Texas

New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.

The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”

Do you wake up every morning dreading going to work? If this happens to you even once a week, it may be time to start looking for a new gig.

Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

Biopharma companies strengthen their leadership and boards with these appointments.

AuroLase Therapy is a focal ablation treatment utilizing gold nanoparticles. The nanoparticles heat and destroy cancer cells.

Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.

Researchers led by Texas A&M University’s College of Veterinary Medicine & Biomedical Sciences have identified a new pathway they believe may help suppress the development of glioblastoma tumors.

Part of the new corporate park will be used to expand the company’s blood-based diagnostic tests in addition to blood-based molecular profiling and increasing research and development capacity.

Carbon nanotubes are a type of nanomaterials made up of a two-dimensional lattice of carbon atoms. Researchers at Texas Heart Institute recently used bio-compatible nanotubes invented at Rice University to restore electrical function to damaged hearts.